A citation-based method for searching scientific literature

Omar Azzam, Vance B Matthews, Markus P Schlaich. Curr Opin Nephrol Hypertens 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1).
Lubing Zhou, Ellen V Cryan, Michael R D'Andrea, Stanley Belkowski, Bruce R Conway, Keith T Demarest. J Cell Biochem 2003
137
100

Association of type 2 diabetes mellitus with the development of new-onset atrial fibrillation in patients with non-ischemic dilated cardiomyopathy: impact of SGLT2 inhibitors.
Hidekazu Tanaka, Kazuhiro Tatsumi, Hiroki Matsuzoe, Fumitaka Soga, Kensuke Matsumoto, Ken-Ichi Hirata. Int J Cardiovasc Imaging 2021
3
100


Intracellular Na+ Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+-Glucose Cotransport.
Rebekah Lambert, Sarah Srodulski, Xiaoli Peng, Kenneth B Margulies, Florin Despa, Sanda Despa. J Am Heart Assoc 2015
64
100


Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects.
Jason R B Dyck, Samuel Sossalla, Nazha Hamdani, Ruben Coronel, Nina C Weber, Peter E Light, Coert J Zuurbier. J Mol Cell Cardiol 2022
4
100

Rationale and design of the EMPYREAN study.
Hirohiko Motoki, Izuru Masuda, Shinji Yasuno, Koji Oba, Wataru Shoin, Satoru Usami, Yoshihiko Saito, Masako Waki, Mitsuhisa Komatsu, Kenji Ueshima,[...]. ESC Heart Fail 2020
6
100


A Meta-Analysis of the Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure and Preserved Ejection Fraction.
Ahmad Al-Abdouh, Mohammed Mhanna, Mahmoud Barbarawi, Waiel Abusnina, Vedant A Gupta. Am J Cardiol 2022
2
100

The implications of obesity for cardiac arrhythmia mechanisms and management.
Rajeev K Pathak, Rajiv Mahajan, Dennis H Lau, Prashanthan Sanders. Can J Cardiol 2015
55
100

Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
Nan Zhang, Yueying Wang, Gary Tse, Panagiotis Korantzopoulos, Konstantinos P Letsas, Qingpeng Zhang, Guangping Li, Gregory Y H Lip, Tong Liu. Eur J Prev Cardiol 2022
8
100

Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death.
Zhaoyang Hu, Feng Ju, Lei Du, Geoffrey W Abbott. Cardiovasc Diabetol 2021
11
100

The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity.
Ningning Wan, Asadur Rahman, Hirofumi Hitomi, Akira Nishiyama. Front Endocrinol (Lausanne) 2018
53
100

Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure.
Takuto Hamaoka, Hisayoshi Murai, Tadayuki Hirai, Hiroyuki Sugimoto, Yusuke Mukai, Oto Inoue, Shinichiro Takashima, Takeshi Kato, Shigeo Takata, Soichiro Usui,[...]. J Am Heart Assoc 2021
4
100

Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia.
Mohammed Ali Azam, Praloy Chakraborty, Daoyuan Si, BeiBei Du, Stéphane Massé, Patrick F H Lai, Andrew C T Ha, Kumaraswamy Nanthakumar. Life Sci 2021
11
100

The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.
Arne Ring, Tobias Brand, Sreeraj Macha, Kerstin Breithaupt-Groegler, Gudrun Simons, Beate Walter, Hans J Woerle, Uli C Broedl. Cardiovasc Diabetol 2013
29
100

Empagliflozin significantly attenuates sotalol-induced QTc prolongation in rats.
Veysel Özgür Barış, Berk Dinçsoy, Esra Gedikli, Ayşen Erdemb. Kardiol Pol 2021
8
100

Sodium-glucose cotransporters: Functional properties and pharmaceutical potential.
Ryuhei Sano, Yuichi Shinozaki, Takeshi Ohta. J Diabetes Investig 2020
23
100

The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study.
Hung-Yi Chen, Jing-Yang Huang, Wun-Zhih Siao, Gwo-Ping Jong. Cardiovasc Diabetol 2020
25
100

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors.
Fan Yang, Ran Meng, Da-Long Zhu. Chronic Dis Transl Med 2020
2
100

SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
Wen-Jie Li, Xing-Qing Chen, Ling-Ling Xu, Yuan-Qing Li, Bi-Hui Luo. Cardiovasc Diabetol 2020
37
100


Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Arjun K Pandey, Iva Okaj, Hargun Kaur, Emilie P Belley-Cote, Jia Wang, Alireza Oraii, Alexander P Benz, Linda S B Johnson, Jack Young, Jorge A Wong,[...]. J Am Heart Assoc 2021
5
100

Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors.
Sarayut Lahnwong, Siriporn C Chattipakorn, Nipon Chattipakorn. Cardiovasc Diabetol 2018
79
100

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF.
David Bode, Lukas Semmler, Paulina Wakula, Niklas Hegemann, Uwe Primessnig, Nicola Beindorff, David Powell, Raphael Dahmen, Hartmut Ruetten, Christian Oeing,[...]. Cardiovasc Diabetol 2021
23
100

Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?
Salva R Yurista, Herman H W Silljé, Michiel Rienstra, Rudolf A de Boer, B Daan Westenbrink. Cardiovasc Diabetol 2020
17
100


Cardioprotection by SGLT2 Inhibitors-Does It All Come Down to Na+?
Maximilian Trum, Johannes Riechel, Stefan Wagner. Int J Mol Sci 2021
14
100

Cardiovascular outcome in type 2 diabetes and atrial fibrillation.
A Costard-Jäckle, D Tschöpe, T Meinertz. Herz 2019
6
100

Effect of SLGT2 Inhibitors on Patients with Atrial Fibrillation.
Justin Haloot, Lucijana Krokar, Auroa Badin. J Atr Fibrillation 2021
1
100

The role of late I Na in development of cardiac arrhythmias.
Charles Antzelevitch, Vladislav Nesterenko, John C Shryock, Sridharan Rajamani, Yejia Song, Luiz Belardinelli. Handb Exp Pharmacol 2014
97
100

Effects of Sodium/Glucose Cotransporter Inhibitors on Atrial Fibrillation and Stroke: A Meta-Analysis.
How Ting Ong, Yao Hao Teo, Yao Neng Teo, Nicholas Lx Syn, Caitlin Fern Wee, Shariel Leong, Alicia Swee Yan Yip, Ray Meng See, Adriel Zhi Hen Ting, Alys Zq Chia,[...]. J Stroke Cerebrovasc Dis 2022
4
100


The role of the autonomic nervous system in cardiac arrhythmias: The neuro-cardiac axis, more foe than friend?
Antonis A Manolis, Theodora A Manolis, Evdoxia J Apostolopoulos, Naomi E Apostolaki, Helen Melita, Antonis S Manolis. Trends Cardiovasc Med 2021
13
100

6
100

Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.
W Timothy Garvey, Luc Van Gaal, Lawrence A Leiter, Ujjwala Vijapurkar, James List, Robert Cuddihy, Jimmy Ren, Michael J Davies. Metabolism 2018
108
100

Cardiovascular Safety of Antihyperglycemic Agents: "Do Good or Do No Harm".
Antonis A Manolis, Theodora A Manolis, Antonis S Manolis. Drugs 2018
3
100

The Off-Target Effects, Electrolyte and Mineral Disorders of SGLT2i.
Giuseppe Cianciolo, Antonio De De Pascalis, Lorenzo Gasperoni, Francesco Tondolo, Fulvia Zappulo, Irene Capelli, Maria Cappuccilli, Gaetano La La Manna. Molecules 2020
8
100


Potential roles of sodium-glucose co-transporter 2 inhibitors in attenuating cardiac arrhythmias in diabetes and heart failure.
Tanawat Attachaipanich, Siriporn C Chattipakorn, Nipon Chattipakorn. J Cell Physiol 2022
1
100

Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin.
Koenraad Philippaert, Subha Kalyaanamoorthy, Mohammad Fatehi, Wentong Long, Shubham Soni, Nikole J Byrne, Amy Barr, Jyoti Singh, Jordan Wong, Taylor Palechuk,[...]. Circulation 2021
31
100

Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials.
Victor Okunrintemi, Basem M Mishriky, James R Powell, Doyle M Cummings. Diabetes Obes Metab 2021
20
100


Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials.
Gilson C Fernandes, Amanda Fernandes, Rhanderson Cardoso, Jorge Penalver, Leonardo Knijnik, Raul D Mitrani, Robert J Myerburg, Jeffrey J Goldberger. Heart Rhythm 2021
24
100

Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
Thomas A Zelniker, Marc P Bonaca, Remo H M Furtado, Ofri Mosenzon, Julia F Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding,[...]. Circulation 2020
113
100

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system.
Benedetta Maria Bonora, Emanuel Raschi, Angelo Avogaro, Gian Paolo Fadini. Cardiovasc Diabetol 2021
16
100

Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition.
Lakshini Y Herat, Jennifer Matthews, Omar Azzam, Markus P Schlaich, Vance B Matthews. Curr Hypertens Rep 2022
3
100

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Stefan D Anker, Javed Butler, Gerasimos Filippatos, João P Ferreira, Edimar Bocchi, Michael Böhm, Hans-Peter Brunner-La Rocca, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure-Valenzuela,[...]. N Engl J Med 2021
449
100

Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model.
Ryo Nishinarita, Shinichi Niwano, Hiroe Niwano, Hironori Nakamura, Daiki Saito, Tetsuro Sato, Gen Matsuura, Yuki Arakawa, Shuhei Kobayashi, Yuki Shirakawa,[...]. J Am Heart Assoc 2021
11
100

SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.
Sanjay K Banerjee, Kenneth R McGaffin, Núria M Pastor-Soler, Ferhaan Ahmad. Cardiovasc Res 2009
142
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.